Oct-1 recombinant monoclonal antibody

Oct-1 recombinant monoclonal antibody

Seller Gentaur · Catalog number: A5840

Category product: Business and Industry > Scientific and Laboratory Research

 (0) Reviews
Availability: Made to order
Price

0.01 USD*

Size
100ul X 3
Oct-1 recombinant monoclonal antibody
Oct-1 recombinant monoclonal antibody

Catalog number: / Size: / Price : USDtest product-price-currency (VAT free)

Inquiry cart
1
Adres Email: | Edit
2
Details of the inquiry
Oct-1 recombinant monoclonal antibody
Oct-1 recombinant monoclonal antibody

Catalog number: A5840 / Size: 100ul X 3 / Price: 0.01 USD (VAT free)

3
Inquiry cart
* Net price, excluding transport costs. Contact us to receive the current offer within 24 hours.
A recombinant monoclonal antibody from rabbit against human Oct-1 for WB,ELISA
  • Specifications:
    • Host: Rabbit
    • Species reactivity: Human
    • Clonality: Recombinant monoclonal antibody
    • Recognized antigen: Oct-1
    • Concentration: 1mg/ml
    • Tested applications: WB,ELISA
    • Form: Liquid
    • Buffer compositions: 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Slight variations in the buffer composition may be made in order to improve the quality of the antibodies. Please, inquire for the composition of the latest storage buffer.
    • Conjugation: Unconjugated
  • Storage and shipping:Shipped on ice packs. Upon receipt store frozen at -20 degrees Celsius.
  • Notes:For research use only. Not to be used for diagnostics or treatment.
  • Additional informations: Comparisons between Mnoclonal, Polyclonal and Recombinant antibodies and their benefits: Regular monoclonal antibodies have higher purity, better specificity and less lot-to-lot variations than polyclonal antibodies. Recombinant antibodies, however, are even superior to the normal monoclonal antibodies in terms of purity and specificity and the batch-to-batch variation is virtually nonexistant. Until recently their only downside used to be the higher production costs and longer lead time but as the technology progressed and was scaled up both the cost and the delivery time were reduced to levels comparable to those of normal monoclonal and many polyclonal antibodies.